We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Showcases Innovative Solutions for Molecular Diagnostics and Immunoassays

By LabMedica International staff writers
Posted on 11 Nov 2024

Meridian Bioscience (Cincinnati, OH, USA) is presenting its innovative solutions in molecular and immunoassay reagents that are designed to simplify assay design, eliminate cold-chain logistics, and improve sustainability. More...

The company is also highlighting its large portfolio of antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR, isothermal amplification, and NGS applications for the IVD industry.

Meridian’s glycerol-free, high-concentration molecular reagents, and services enable the development of ambient-temperature stable assays, eliminating the need for cold chain logistics and ensuring robust and seamless supply chains. This reduces energy consumption in transit and storage as well as minimizes packaging requirements, particularly the use of refrigerant, dry ice, and expanded polystyrene foam. Meridian’s extraction-free, low-temperature molecular solutions streamline workflows by eliminating the need for multiple reagent-based extraction steps and reducing the overall energy consumption required for high-temperature processes. Streamlined workflows with fewer steps result in faster turnaround times and increased throughput, reducing operational energy and resource use. Additionally, Meridian’s animal-free recombinant alternatives for immunoassays (blockers, antibodies, and antigens) can offer greater versatility and reproducibility over animal immunization, ensuring continuity of supply while alleviating ethical concerns.

Meridian is highlighting its recently launched glycerol-free NGS enzymes, further establishing the company as a leader in developing innovative, eco-conscious, and cost-effective components for diagnostic assay developers. Visitors to Meridian’s booth at the show can also learn about the company’s introduction of the market’s first innovative lyophilized Next-Generation Sequencing (NGS) library preparation kit. This revolutionary lyophilized NGS library preparation kit, designed initially for sequencing by synthesis (SBS) protocols, marks a breakthrough in stabilizing the library preparation process at room temperature. The pioneering kit can be transported and stored at ambient temperature and contains ready-to-use lyophilized reactions to simplify the end-repair, A-tailing, ligation, and library amplification steps of most sequencing protocols. By eliminating the requirement for cold-chain shipping and storage, Meridian’s innovative kit not only simplifies logistical and environmental challenges but also significantly reduces carbon emissions and operational costs, thereby streamlining the entire NGS workflow.

Related Links:
Meridian Bioscience


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.